Drug Profile
NI 0801
Alternative Names: Alpha-IP-10; EB 06; NI-0801; α-IP-10Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator NovImmune SA
- Developer Edesa Biotech; NovImmune SA
- Class Antiallergics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Chemokine CXCL10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute lung injury; Adult respiratory distress syndrome; Vitiligo
- Discontinued Allergic contact dermatitis; Primary biliary cirrhosis
Most Recent Events
- 10 Jul 2023 Phase-II clinical trials in Vitiligo in Canada (IV) (Light Chain Bioscience pipeline, July 2023)
- 01 Feb 2023 Preclinical trials in Vitiligo in Canada (IV) (Edesa biotech pipeline, February 2023)
- 01 Feb 2023 Health Canada approves phase II clinical study for EB 06 in Vitiligo (In adults) (IV)